[1] Chalabi M, et al. Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2. 2024 ESMO LBA24.
[2] GOOYER P D, VERSCHOOR Y, DUNGEN L V, et al. Neoadjuvant nivolumab plus Relatlimab in MMR-deficient Colon Cancer: Results of the NICHE-3 Study. 2024 ESMO. 503O.
[3] Tougeron D et al. Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial.2024 ESMO 502O.
[4] Deng Y, et al. The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC).2024 ESMO 514MO.
[5] Prager GW, et al; SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023 May 4;388(18):1657-1667.
[6] Wakabayashi M, et al. A phase Il study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study).2024 ESMO 523P.
[7] Li J, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018 Jun 26;319(24):2486-2496.
[8] Dasari A,et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53.
[9] Garcia-Carbonero G, et al. Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial.2024 ESMO 520Р.
[10] Elez Fernandez M.E, et al. Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age.2024 ESMO 526Р.
[11] Pietrantonio F, et al. Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/ll study.2024 ESMO 513MO.
[12] Hendifar A, et al. Phase Ib/ll study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results.2024 ESMO 575Р.
[13] Siena S, et al. Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study.2024 ESMO 505O.
